Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...101102103104105106107108109110111...123124»
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
    Comprehensive analysis for genomic features of stem cell-like hepatocellular carcinoma (Virtual Meeting II: E-Posters) -  May 16, 2020 - Abstract #AACRII2020AACR-II_2037;    
    We identified subtype-specific serum and tissue biomarkers for the stem cell-like subtypes and precise therapeutic strategies for each subtype regarding immunotherapy and molecular-targeted treatment. Our findings may offer the theoretical foundation of biomarker-based clinical trials for new therapeutic approaches to resectable early-stage HCC patients.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed, Trial primary completion date, Metastases:  Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma (clinicaltrials.gov) -  May 14, 2020   
    P1,  N=20, Active, not recruiting, 
    These differences may have contributed to the observed variation in results between the 2 studies. Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2020 --> Oct 2019
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
    Clinical, Journal:  Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. (Pubmed Central) -  May 14, 2020   
    No significant differences were observed in median ΔSMI between patients with and without progressive disease (-2.35 and -1.1 cm2/m2/months, respectively), albumin-bilirubin grade 1 and 2 group disease (-1.7 and -1.5 cm2/m2/months, respectively), and relative dose intensity ≤80 and >80 (-1.8 and -1.2 cm2/m2/months, respectively). This report demonstrated that patients receiving TKI treatment experienced a significant loss of skeletal muscle mass regardless of disease progression, hepatic reserve, or which TKI (sorafenib or lenvatinib) they received.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal:  Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape. (Pubmed Central) -  May 13, 2020   
    Positioning of these immunotherapies in the landscape may or may not have impacts upon sequencing of all of the available therapies. Further studies are ongoing investigating such sequencing questions, in addition to more novel agents to combat this devastating disease.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal:  Multikinase Inhibitor Treatment in Thyroid Cancer. (Pubmed Central) -  May 6, 2020   
    The objective of this review is to give an update on MKI treatment (lenvatinib, sorafenib, sunitinib, cabozantinib, pazopanib, vandetanib) of thyroid cancer, regarding its efficacy and safety profile...The AEs are often more severe in patients with high efficacy of MKIs, which could indicate a correlation. Taken together, the novel therapeutic regimen with MKIs has shown favorable results in otherwise treatment-resistant thyroid cancer.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    [VIRTUAL] Safety and efficacy of lenvatinib in HCC beyond second-line treatment. () -  Apr 29, 2020 - Abstract #ASCO2020ASCO_4066;    
    Lenvatinib is a promising agent for treating advanced HCC in a later treatment line and revealed a tolerable toxicity profile. Research Funding: None